NCT06306339 - A Study to Assess the Efficacy and Safety of Burfiralimab (hzVSF-v13) and DMRD (Disease-modifying Antirheumatic Drug) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2024

Primary Completion Date

May 31, 2025

Study Completion Date

July 31, 2025

Conditions

Moderate to Severe Rheumatoid Arthritis

Interventions

DRUG

Burfiralimab

Humanized monoclonal antibody.

DRUG

SOC (Standard of care)

"The following medications listed are allowed to be administered during the course of the clinical study.~1. biologic disease-modifying antirheumatic drug (bDMARD)~2. conventional synthetic disease-modifying antirheumatic drug (csDMARD)"

DRUG

Placebo

The placebo for Burfiralimab (hzVSF-v13)

Trial Locations (1)

Unknown

University Medical Center Urtrecht, Utrecht